You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Integrating a suite of mental health apps for depression in a healthcare setting.

    SBC: Adaptive Health, Inc.            Topic: 104

    Abstract Depression is common, imposing a tremendous societal burden in terms of cost, morbidity, quality of life, and mortality. The great majority of people with depression are treated in primary care, however outcomes remain poor. There have been two broad attempts to address this problem. One is collaborative care, which uses care managers to coordinate patient care. Collaborative care can be ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. An Integrated CT-based Image-Guided Neurosurgical System

    SBC: Xoran Technologies LLC            Topic: 102

    An Integrated CT-based Image-Guided Neurosurgical System In this SBIR Phase IIb proposal Xoran intends to commercialize a compact and affordable, yet highly- functional, system to provide real time image updates and navigation guidance in support of minimally invasive cranial and spinal neurosurgical procedures. The effort builds on previously developed compact and portable flat-panel Computed Tom ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Microneedle Delivery of Zanamivir for Treatment of Influenza

    SBC: TSRL, INC.            Topic: NIAID

    Abstract Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is andlt;0.03%, but with significant mortality in the young and the elderly populations. When a new pathogenic influenza strain enters the population, a pandemic could kill tens of millions of people with a negative economic impact estimated to be over 150 ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Cardiac Ventricular Assist Catheter

    SBC: MICHIGAN CRITICAL CARE CONSULTANTS, INC.            Topic: NICHD

    ABSTRACTExtracorporeal membrane oxygenation (ECMO) use continues to increase as a supportive measure for cardio-respiratory failure. Pediatric patients with severe, acute left ventricular (LV) systolic dysfunction are often supported with venoarterial (VA) ECMO as a short-term bridge to recovery, transplant or a ventricular assist device (VAD). ECMO provides temporary gas exchange and increased ca ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a peptide-based oral drug to prevent kidney stones

    SBC: Oxalo Therapeutics, Inc.            Topic: 400

    Project Summary/Abstract Kidney stones (KS) are highly prevalent, excruciating, and associated with long term complications of chronic kidney disease (CKD) and end stage renal disease (ESRD). They account for 1.3M ER visits and andgt;$10B of medical costs annually and have a striking recurrence rate of 50% in 5 years and up to 80% in 10 years, reflecting the inadequacies of current interventions. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Array Based Affinity Selection

    SBC: Tango Biosciences Inc.            Topic: 300

    Project Summary Funds are requested to apply technologies being developed in a current NIGMS award to generate recombinant antibody-like affinity reagents to the spike protein of the SARS-CoV-2 virus. As a proof-of-principle experiment, we have already isolated four fibronectin type III (FN3) monobodies that bind with low nanomolar affinity to the receptor binding domain (RBD) of the viral spike p ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Articulating Video Stylet for Improved Intubation Success Rates

    SBC: BRIO DEVICE, LLC            Topic: NHLBI

    Project SummaryMore than 20 million intubations are performed in the US every year and may carry a high rate of procedure-related and disease-related complications. The higher incidence of difficult intubation in children is due to a more anterior larynx and presence of congenital syndromes resulting in 20% suffering complications during and related to airway management. Difficult intubations in p ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Bioresorbable Nanoparticles for Visual Detection of Early-Stage Dental Caries

    SBC: GreenMark Biomedical Inc.            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACT This project responds to the need identified by NIDCR to develop improved methods to detect and predict progression of dental caries (tooth decay) to improve human health. Worldwide, caries is the most common chronic disease affecting almost everyone. Dental disease is a major cause of economic and social loss and leads to complications including pain, tooth loss and even ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury

    SBC: Mitovation, Inc.            Topic: 101

    Neonatal hypoxia/ischemia is a known cause of cerebral damage resulting from inadequate blood flow and/or oxygen delivery to the infant brain before, during, or after birth. The occurrence among hospital deliveries is ~2-4 per 1000 full-term births with a drastic increase among premature newborns. The deficit in oxygen delivery to the brain results in extensive damage and severe disabilities. Rest ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government